Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Olson

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Molecular Pharmaceutics|April 24, 2018
ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor XenograftsSarah M Cheal, Shutian Ruan, Darren R Veach, et al.
Molecular Cancer Therapeutics|July 28, 2021
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway BlockadeJohn O DaSilva, Katie Yang, Oliver Surriga, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
Plos One|May 9, 2020
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5Adrianna Latuszek, Yashu Liu, Olav Olsen, et al.
Blood|June 11, 2026
Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)Dan Chalothorn, Aaron Paul Kithcart, Ethan Marin, et al.
The Journal of Infectious Diseases|September 6, 2008
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adultsJeffrey M Jacobson, Michael S Saag, Melanie A Thompson, et al.
Science Translational Medicine|June 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancerAlison Crawford, Lauric Haber, Marcus P Kelly, et al.
Cancer Immunology Research|July 27, 2022
Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054Richard Tavaré, Makenzie Danton, Jason T Giurleo, et al.
Cell Reports. Medicine|September 26, 2024
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapiesJiaxi Wu, Nicolin Bloch, Aaron Y Chang, et al.
Science (New York, N.Y.)|October 15, 2011
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shieldRobert Pejchal, Katie J Doores, Laura M Walker, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Molecular Pharmaceutics|April 24, 2018
ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor XenograftsSarah M Cheal, Shutian Ruan, Darren R Veach, et al.
Molecular Cancer Therapeutics|July 28, 2021
A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway BlockadeJohn O DaSilva, Katie Yang, Oliver Surriga, et al.
The Prostate|November 20, 2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 studyDaniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, et al.
Plos One|May 9, 2020
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5Adrianna Latuszek, Yashu Liu, Olav Olsen, et al.
Blood|June 11, 2026
Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)Dan Chalothorn, Aaron Paul Kithcart, Ethan Marin, et al.
The Journal of Infectious Diseases|September 6, 2008
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adultsJeffrey M Jacobson, Michael S Saag, Melanie A Thompson, et al.
Science Translational Medicine|June 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancerAlison Crawford, Lauric Haber, Marcus P Kelly, et al.
Cancer Immunology Research|July 27, 2022
Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054Richard Tavaré, Makenzie Danton, Jason T Giurleo, et al.
Cell Reports. Medicine|September 26, 2024
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapiesJiaxi Wu, Nicolin Bloch, Aaron Y Chang, et al.
Science (New York, N.Y.)|October 15, 2011
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shieldRobert Pejchal, Katie J Doores, Laura M Walker, et al.
Pageof 8